Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length), published as a clinical trial.

The aim of the study was to assess the influence of the exon 3-deleted (d3-GHR) and full-length (fl-GHR) GH receptor isoforms on the response to GH replacement therapy in adults with severe GHD.

Why It Was Studied

There is considerable individual variation in the clinical response to GH replacement therapy in GH deficient (GHD) adults.

Useful predictors of treatment response are lacking.

Who Took Part

The study group was 124 patients.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

GHD patients were divided into those bearing fl/fl alleles (group 1) and those bearing at least one d3-GHR allele (group 2), and the genotype was related to the effects of GH therapy on IGF-I levels and total body fat (BF).

What Was Measured

The subject headings attached to it are Exons, Gene Deletion, Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Longitudinal Studies and Polymorphism, Genetic.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length) in 124 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Thymosin Beta-4 (full length) compound page, all human trials.